Eupraxia Pharmaceuticals is trading at $7.42, down 5.24%, with no clear company-specific catalyst identified for October 2.

  • The shares were also down 13.96% at the October 1 close, after rising September 30 following reported 52-week trial data.
  • H.C. Wainwright reiterated its Buy rating after the update, but that coverage does not explain the decline.
  • Major indexes were higher, so broad-market weakness was not an evident explanation; the reason remains unclear.